adefovir dipivoxil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antivirals	88	142340-99-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: adefovir dipivoxil hepsera preveon	inhibitor of African swine fever virus Molecular weight: 501.48 Formula: C20H32N5O8P CLOGP: 1.40 LIPINSKI: 2 HAC: 13 HDO: 1 TPSA: 166.98 ALOGS: -2.90 ROTB: 15 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

adefovir dipivoxil
hepsera
preveon

inhibitor of African swine fever virus

Molecular weight: 501.48
Formula: C20H32N5O8P
CLOGP: 1.40
LIPINSKI: 2
HAC: 13
HDO: 1
TPSA: 166.98
ALOGS: -2.90
ROTB: 15

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ
S (Water solubility)	0.40 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	45 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.43 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	12 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
March 6, 2003	EMA
Sept. 20, 2002	FDA	GILEAD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Osteomalacia	631.22	53.28	86	1708	659	63486569
Fanconi syndrome acquired	452.59	53.28	67	1727	969	63486259
Hypophosphataemia	330.02	53.28	74	1720	11352	63475876
Drug resistance	213.33	53.28	60	1734	22873	63464355
Osteoporosis	166.61	53.28	62	1732	57276	63429952
Bone pain	154.76	53.28	58	1736	54583	63432645
Hypophosphataemic osteomalacia	149.76	53.28	21	1773	199	63487029
Fanconi syndrome	143.07	53.28	26	1768	1366	63485862
Blood phosphorus decreased	129.12	53.28	29	1765	4424	63482804
Renal tubular disorder	114.43	53.28	24	1770	2658	63484570
Hepatitis B DNA increased	91.12	53.28	14	1780	259	63486969
Viral load increased	80.45	53.28	16	1778	1358	63485870
Hypouricaemia	75.15	53.28	11	1783	144	63487084
Pathogen resistance	74.41	53.28	20	1774	6378	63480850
Viral mutation identified	70.33	53.28	15	1779	1795	63485433
Aminoaciduria	69.12	53.28	10	1784	120	63487108
Blood alkaline phosphatase increased	67.66	53.28	30	1764	42937	63444291
Glycosuria	58.85	53.28	12	1782	1154	63486074
Renal tubular dysfunction	57.05	53.28	10	1784	425	63486803

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Osteomalacia	1784.18	53.18	274	5577	643	34950437
Hypophosphataemia	935.05	53.18	240	5611	10786	34940294
Fanconi syndrome acquired	861.47	53.18	165	5686	1826	34949254
Drug resistance	482.56	53.18	176	5675	25751	34925329
Osteoporosis	429.39	53.18	135	5716	12533	34938547
Fanconi syndrome	405.08	53.18	86	5765	1634	34949446
Blood phosphorus decreased	383.24	53.18	92	5759	3089	34947991
Viral mutation identified	369.14	53.18	88	5763	2866	34948214
Hypophosphataemic osteomalacia	357.78	53.18	53	5798	84	34950996
Bone pain	310.10	53.18	120	5731	20566	34930514
Hepatitis B DNA increased	245.09	53.18	47	5804	518	34950562
Multiple fractures	216.78	53.18	50	5801	1402	34949678
Hypouricaemia	199.03	53.18	35	5816	227	34950853
Blood alkaline phosphatase increased	195.38	53.18	98	5753	31077	34920003
Renal tubular disorder	188.87	53.18	57	5794	4586	34946494
Bone density decreased	177.67	53.18	45	5806	1884	34949196
Pathogen resistance	163.48	53.18	61	5790	9421	34941659
Urine phosphorus increased	156.99	53.18	23	5828	32	34951048
Viral load increased	156.31	53.18	43	5808	2484	34948596
Hepatic cancer	138.13	53.18	52	5799	8223	34942857
Multiple-drug resistance	125.41	53.18	43	5808	5196	34945884
Blood creatinine increased	125.33	53.18	113	5738	94863	34856217
Glycosuria	109.67	53.18	28	5823	1209	34949871
Renal impairment	102.69	53.18	101	5750	94412	34856668
Proteinuria	94.81	53.18	51	5800	18591	34932489
Aminoaciduria	94.51	53.18	19	5832	271	34950809
Glucose urine present	93.89	53.18	24	5827	1041	34950039
Hepatocellular carcinoma	92.91	53.18	38	5813	7471	34943609
Hepatitis B reactivation	89.48	53.18	31	5820	3860	34947220
Gait disturbance	88.77	53.18	89	5762	85051	34866029
Arthralgia	87.75	53.18	124	5727	169917	34781163
Renal tubular dysfunction	86.96	53.18	19	5832	413	34950667
Renal glycosuria	84.55	53.18	12	5839	11	34951069
Genotype drug resistance test positive	82.58	53.18	22	5829	1123	34949957
Urine phosphorus decreased	82.29	53.18	13	5838	38	34951042
Hepatitis B	79.94	53.18	32	5819	5951	34945129
Urine calcium increased	74.32	53.18	12	5839	42	34951038
Bone marrow oedema	68.45	53.18	17	5834	655	34950425
Fracture	65.90	53.18	29	5822	6820	34944260
Blood uric acid decreased	62.78	53.18	14	5837	335	34950745
Protein urine present	59.73	53.18	25	5826	5203	34945877
Alanine aminotransferase increased	55.59	53.18	68	5783	80747	34870333

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Osteomalacia	2289.81	46.89	330	6179	1150	79736729
Hypophosphataemia	1185.00	46.89	283	6226	19630	79718249
Fanconi syndrome acquired	1159.06	46.89	199	6310	2495	79735384
Drug resistance	557.91	46.89	185	6324	42028	79695851
Hypophosphataemic osteomalacia	505.97	46.89	74	6435	286	79737593
Viral mutation identified	482.93	46.89	101	6408	3757	79734122
Osteoporosis	475.56	46.89	175	6334	53937	79683942
Fanconi syndrome	434.98	46.89	88	6421	2768	79735111
Bone pain	408.88	46.89	158	6351	55584	79682295
Blood phosphorus decreased	386.31	46.89	93	6416	6575	79731304
Pathogen resistance	263.85	46.89	81	6428	14261	79723618
Hepatitis B DNA increased	241.97	46.89	44	6465	771	79737108
Blood alkaline phosphatase increased	234.89	46.89	111	6398	63553	79674326
Hypouricaemia	234.49	46.89	39	6470	393	79737486
Renal tubular disorder	219.89	46.89	59	6450	6427	79731452
Viral load increased	201.32	46.89	47	6462	2901	79734978
Urine phosphorus increased	186.24	46.89	26	6483	65	79737814
Glycosuria	160.63	46.89	37	6472	2151	79735728
Multiple-drug resistance	150.35	46.89	47	6462	8761	79729118
Renal tubular dysfunction	148.76	46.89	29	6480	748	79737131
Hepatitis B reactivation	144.85	46.89	42	6467	6066	79731813
Bone density decreased	138.77	46.89	49	6460	13298	79724581
Multiple fractures	137.71	46.89	43	6466	7983	79729896
Genotype drug resistance test positive	128.11	46.89	28	6481	1280	79736599
Proteinuria	123.81	46.89	58	6451	32444	79705435
Hepatocellular carcinoma	120.65	46.89	40	6469	8981	79728898
Hepatic cancer	118.45	46.89	41	6468	10488	79727391
Renal impairment	118.43	46.89	100	6409	157683	79580196
Renal glycosuria	112.68	46.89	15	6494	22	79737857
Glucose urine present	109.41	46.89	26	6483	1730	79736149
Blood creatinine increased	101.65	46.89	91	6418	154966	79582913
Gait disturbance	96.83	46.89	101	6408	207405	79530474
Aminoaciduria	95.95	46.89	18	6491	376	79737503
Urine phosphorus decreased	90.88	46.89	13	6496	41	79737838
Nephropathy toxic	82.59	46.89	38	6471	20381	79717498
Rib fracture	76.96	46.89	40	6469	27907	79709972
Acquired aminoaciduria	76.26	46.89	10	6499	12	79737867
Blood uric acid decreased	74.70	46.89	18	6491	1270	79736609
Urine calcium increased	74.07	46.89	12	6497	101	79737778
Hyperphosphatasaemia	74.07	46.89	12	6497	101	79737778
Femoral neck fracture	68.38	46.89	27	6482	9957	79727922
Arthralgia	66.79	46.89	145	6364	571658	79166221
Hyperphosphaturia	66.75	46.89	11	6498	104	79737775
Bone marrow oedema	64.79	46.89	17	6492	1694	79736185
Renal tubular acidosis	64.66	46.89	20	6489	3594	79734285
Hepatitis B	58.70	46.89	23	6486	8309	79729570
Muscular weakness	55.59	46.89	67	6442	160662	79577217
Protein urine present	54.39	46.89	23	6486	10089	79727790
Back pain	52.37	46.89	91	6418	304089	79433790
Beta 2 microglobulin urine increased	50.72	46.89	9	6500	136	79737743
Blood phosphorus abnormal	50.32	46.89	10	6499	285	79737594

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J05AF08	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Nucleoside and nucleotide reverse transcriptase inhibitors
FDA MoA	N0000009947	Nucleoside Reverse Transcriptase Inhibitors
FDA EXT	N0000175459	Nucleoside Analog
CHEBI has role	CHEBI:36044	antiviral drugs
CHEBI has role	CHEBI:49103	drug metabolites
CHEBI has role	CHEBI:50909	agente nefrotoxico
CHEBI has role	CHEBI:53756	reverse transcriptase inhibitors
CHEBI has role	CHEBI:59517	DNA synthesis inhibitors
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000998	Antiviral Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D019384	Nucleic Acid Synthesis Inhibitors
MeSH PA	D018894	Reverse Transcriptase Inhibitors
FDA EPC	N0000175656	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
CHEBI has role	CHEBI:50266	Prodrugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chronic type B viral hepatitis	indication	61977001
Kidney disease	contraindication	90708001	DOID:557
Lactic acidosis	contraindication	91273001	DOID:3650
Steatosis of liver	contraindication	197321007
Toxic nephropathy	contraindication	236514003
Breastfeeding (mother)	contraindication	413712001
Obesity	contraindication	414916001	DOID:9970
Drug Resistance to Anti-retroviral Therapy	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.73	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
DNA polymerase subunit gamma-1	Enzyme	P54098	DPOG1_HUMAN				WOMBAT-PK
Protein P	Polyprotein		Q9IF40_HBV	INHIBITOR			CHEMBL	CHEMBL
Capsid protein	Unclassified		Q03732_HBV		EC50	7.08	CHEMBL

External reference:

ID	Source
4021357	VUID
N0000179520	NUI
141400	RXNORM
C0540694	UMLSCUI
CHEBI:31175	CHEBI
CHEBI:2469	CHEBI
CHEMBL922	ChEMBL_ID
DB00718	DRUGBANK_ID
C106812	MESH_SUPPLEMENTAL_RECORD_UI
C053001	MESH_SUPPLEMENTAL_RECORD_UI
U6Q8Z01514	UNII
60871	PUBCHEM_CID
DB13868	DRUGBANK_ID
409114008	SNOMEDCT_US
412072006	SNOMEDCT_US
412073001	SNOMEDCT_US
C0050175	UMLSCUI
CHEMBL484	ChEMBL_ID
4021357	VANDF
4024286	VANDF
7313	INN_ID
106941-25-7	SECONDARY_CAS_RN
60172	PUBCHEM_CID
16958	MMSL
205746	MMSL
44701	MMSL
d04814	MMSL
6GQP90I798	UNII
009376	NDDF
009377	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ADEFOVIR DIPIVOXIL	HUMAN PRESCRIPTION DRUG LABEL	1	42794-003	TABLET	10 mg	ORAL	ANDA	29 sections
ADEFOVIR DIPIVOXIL	HUMAN PRESCRIPTION DRUG LABEL	1	42794-003	TABLET	10 mg	ORAL	ANDA	29 sections
Hepsera	HUMAN PRESCRIPTION DRUG LABEL	1	46014-0501	TABLET	10 mg	ORAL	NDA	32 sections
Adefovir dipivoxil	HUMAN PRESCRIPTION DRUG LABEL	1	60505-3947	TABLET	10 mg	ORAL	ANDA	29 sections
Adefovir dipivoxil	HUMAN PRESCRIPTION DRUG LABEL	1	60505-3947	TABLET	10 mg	ORAL	ANDA	29 sections
Hepsera	HUMAN PRESCRIPTION DRUG LABEL	1	61958-0501	TABLET	10 mg	ORAL	NDA	29 sections
Hepsera	HUMAN PRESCRIPTION DRUG LABEL	1	61958-0501	TABLET	10 mg	ORAL	NDA	29 sections